Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 17/20 | 0.52 |
| ▸ | NR3C1 | P04150 | 15/20 | 0.52 |
| ▸ | NR3C2 | P08235 | 7/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4589637 | 0.84 | PGR (0.47) | PGRNR3C1NR3C2 | |
| SCHEMBL14079653 | 0.84 | PGR (0.47) | PGRNR3C1NR3C2 | |
| SCHEMBL6585383 | 0.84 | PGR (0.66) | PGRNR3C1NR3C2MAPTKDM4E | |
| SCHEMBL6586035 | 0.80 | PGR (0.64) | PGRNR3C1NR3C2MAPTKDM4E | |
| SCHEMBL4590006 | 0.80 | MEN1 (0.44) | PGRNR3C1NR3C2MAPTKDM4E | |
| SCHEMBL14079654 | 0.80 | MEN1 (0.44) | PGRNR3C1NR3C2MAPTKDM4E | |
| SCHEMBL6585839 | 0.80 | PGR (0.62) | PGRNR3C1NR3C2MAPTKDM4E | |
| SCHEMBL13909230 | 0.79 | PGR (0.60) | PGRNR3C1NR3C2MAPTKDM4E | |
| SCHEMBL4161922 | 0.79 | PGR (0.60) | PGRNR3C1NR3C2MAPTKDM4E | |
| SCHEMBL14079658 | 0.79 | PGR (0.43) | PGRNR3C1NR3C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7408060-B2 | Nonsteroidal progesterone receptor modulators | SCHERING AG (DE) | 2008-08-05 | — | — | US | disclosed |
| EP-1899315-A1 | BENZOFURANONE DERIVATIVES AS NONSTEROIDAL PROGESTERONE RECEPTOR MODULATORS | Schering Aktiengesellschaft (DE) | 2008-03-19 | — | — | EP | disclosed |
| US-20070142464-A1 | Nonsteroidal progesterone receptor modulators | SCHERING AG (DE) | 2007-06-21 | — | — | US | disclosed |
| WO-2006136462-A1 | BENZOFURANONE DERIVATIVES AS NONSTEROIDAL PROGESTERONE RECEPTOR MODULATORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2006-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142464-A1 | Nonsteroidal progesterone receptor modulators | PGR, PGRMC1, PGRMC2 | PGR 1/4885NR3C1 86/4885NR3C2 49/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.